Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes.
The patency of the ductus arteriosus is very common in extremely premature infants. The increased pulmonary blood flow that results from left-to-right ductal shunting can produce an acute deterioration in lung function and some data suggest that it may increase the risk of chronic lung damage. However, there is no clear evidence that prophylactic or early closure of the patent ductus arteriosus (PDA) results in a clear reduction in bronchopulmonary dysplasia. For this reason, and because of the side effects of the available therapies to close the ductus, there is a wide variation in the approach to the PDA in this population and most clinicians will intervene to close the ductus only in cases of significant shunt with hemodynamic decompensation.
Division of Neonatology, Department of Pediatrics, University of Miami, Miller School of Medicine, Miami, Florida.
Eduardo
E
Bancalari
D001997:Bronchopulmonary Dysplasia / Q000503:physiopathology*; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy / Q000503:physiopathology*; D006439:Hemodynamics; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D062071:Infant, Extremely Premature; D007231:Infant, Newborn; D008168:Lung / Q000503:physiopathology*; D016032:Randomized Controlled Trials as Topic
D007052:Ibuprofen; D007213:Indomethacin